Background: Renal ischemia reperfusion injury (IRI) leads to acute kidney injury (AKI) and the death of tubular epithelial cells (TEC). The release of high-mobility group box-1 (HMGB1) and other damage-associated molecular pattern moieties from dying cells may promote organ dysfunction and inflammation by effects on TEC. Glycyrrhizic acid (GZA) is a functional inhibitor of HMGB1, but its ability to attenuate the HMGB1-mediated injury of TEC has not been tested. Methods/Results: In vitro, hypoxia and cytokine treatment killed TEC and resulted in the progressive release of HMGB1 into the supernatant. GZA reduced the hypoxia-induced TEC death as measured by annexin-V and propidium iodide. Hypoxia increased the expression of MCP-1 and CXCL1 in TEC, which was reduced by GZA in a dose-dependent manner. Similarly, the HMGB1 activation of effector NK cells was inhibited by GZA. To test the effect of HMGB1 neutralization by GZA in vivo, mice were subjected to renal IRI. HMGB1 protein expression increased progressively in kidneys from 4 to 24 h after ischemia and was detected in tubular cells by 4 h using immunohistochemistry. GZA preserved renal function after IRI and reduced tubular necrosis and neutrophil infiltration by histological analyses and ethidium homodimer staining. Conclusions: Importantly, these data demonstrate for the first time that AKI following hypoxia and renal IRI may be promoted by HMGB1 release, which can reduce the survival of TEC and augment inflammation. Inhibition of the interaction of HMGB1 with TEC through GZA may represent a therapeutic strategy for the attenuation of renal injury following IRI and transplantation.

Keywords:
Glycyrrhizic acid, HMGB1, Inflammation, Renal ischemia reperfusion injury
1.
Shoskes DA, Halloran PF: Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996;155:1831-1840.
2.
Paller MS: Free radical-mediated postischemic injury in renal transplantation. Ren Fail 1992;14:257-260.
3.
Homer-Vanniasinkam S, Crinnion JN, Gough MJ: Post-ischaemic organ dysfunction: a review. Eur J Vasc Endovasc Surg 1997;14:195-203.
4.
Mohib K, Guan Q, Diao H, Du C, Jevnikar AM: Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007;293:F801-F812.
5.
Gobé G, Willgoss D, Hogg N, Schoch E, Endre Z: Cell survival or death in renal tubular epithelium after ischemia-reperfusion injury. Kidney Int 1999;56:1299-1304.
6.
Nogae S, et al: Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. J Am Soc Nephrol 1998;9:620-631.
7.
Du C, et al: Renal tubular epithelial cell apoptosis by Fas-FasL-dependent self-injury can augment renal allograft injury. Transplant Proc 2003;35:2481-2482.
8.
Zhang ZX, et al: NK cells induce apoptosis in tubular epithelial cells and contribute to renal ischemia-reperfusion injury. J Immunol 2008;181:7489-7498.
9.
Rosin DL, Okusa MD: Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol 2011;22:416-425.
10.
Pisetsky D: Cell death in the pathogenesis of immune-mediated diseases: the role of HMGB1 and DAMP-PAMP complexes. Swiss Med Wkly 2011;141:w13256.
11.
Land WG: Injury to allografts: innate immune pathways to acute and chronic rejection. Saudi J Kidney Dis Transpl 2005;16:520-539.
12.
Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: endogenous danger signaling. Mol Med 2008;14:476-484.
13.
Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195.
14.
Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM: HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 2011;15:1023-1035.
15.
Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ: HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950-2954.
16.
Andersson U, Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-162.
17.
Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001;7:315-321.
18.
Tsung A, et al: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-1143.
19.
Ueno H, et al: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004;170:1310-1316.
20.
Andrassy M, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-3226.
21.
Rovere-Querini P, et al: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825-830.
22.
Beyer C, et al: The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun 2012;18:727-737.
23.
Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318-C1325.
24.
Gardella S, et al: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001.
25.
Zhu H, et al: An efficient delivery of DAMPs on the cell surface by the unconventional secretion pathway. Biochem Biophys Res Commun 2011;404:790-795.
26.
Kaczorowski DJ, et al: Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation 2009;87:1455-1463.
27.
Chen L, et al: TLR engagement prevents transplantation tolerance. Am J Transplant 2006;6:2282-2291.
28.
Yu M, et al: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006;26:174-179.
29.
Krüger B, et al: Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009;106:3390-3395.
30.
Wu H, et al: TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007;117:2847-2859.
31.
Park JS, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-C924.
32.
Andersson U, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-570.
33.
Tsuboi N, et al: Roles of Toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J Immunol 2002;169:2026-2033.
34.
Wu H, et al: HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010;21:1878-1890.
35.
Junhua L, et al: Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischemic reperfusion injury. Nephrol Dial Transplant 2011;26:469-478.
36.
Veldt BJ, et al: Long-term clinical outcome and effect of glycyrrhizin in 1,093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 2006;41:1087-1094.
37.
Mabuchi A, Wake K, Marlini M, Watanabe H, Wheatley AM: Protection by glycyrrhizin against warm ischemia-reperfusion-induced cellular injury and derangement of the microcirculatory blood flow in the rat liver. Microcirculation 2009;16:364-376.
38.
Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H: Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther 2011;339:93-98.
39.
Kang DG, Sohn EJ, Mun YJ, Woo WH, Lee HS: Glycyrrhizin ameliorates renal function defects in the early phase of ischemia-induced acute renal failure. Phytother Res 2003;17:947-951.
40.
Mollica L, et al: Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007;14:431-441.
41.
Edwards JR, Diamantakos EA, Peuler JD, Lamar PC, Prozialeck WC: A novel method for the evaluation of proximal tubule epithelial cellular necrosis in the intact rat kidney using ethidium homodimer. BMC Physiol 2007;7:1.
42.
Suzuki C, et al: Participation of autophagy in renal ischemia/reperfusion injury. Biochem Biophys Res Commun 2008;368:100-106.
43.
Prodjosudjadi W, et al: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 1995;48:1477-1486.
44.
Gong G, et al: Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacol Sin 2012;33:11-18.
45.
Linkermann A, et al: Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 2012;81:751-761.
46.
Lau A, et al: RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant 2013;11:2805-2818.
47.
Kazama H, et al: Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008;29:21-32.
48.
Zhai CL, et al: Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin 2012;33:1477-1487.
49.
Hung CC, et al: Upregulation of chemokine CXCL1/KC by leptospiral membrane lipoprotein preparation in renal tubule epithelial cells. Kidney Int 2006;69:1814-1822.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.